Lyophilised haemostat platelet derivatives - Cellphire

Drug Profile

Lyophilised haemostat platelet derivatives - Cellphire

Alternative Names: Freeze-dried platelets - Cellphire; Thrombosomes

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellphire
  • Class Antihaemorrhagics; Blood products and substitutes; Cell therapies
  • Mechanism of Action Blood coagulation stimulants; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Haemorrhage

Most Recent Events

  • 06 Mar 2018 Lyophilised haemostat platelets - Cellphire is available for licensing as of 06 Mar 2018.
  • 01 Jan 2018 Cellphire initiates a phase I trial in Haemorrhage in USA (Topical) (NCT03394755)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top